Karpov IuA

2 ta ish

National Medical Research Center of Cardiology

1. Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement

   С. Н. Терещенко, М. В. Шестакова, Ф. Т. Агеев +7

   Maqola20202 iqtibos

   ABIABI:AkademIndex/2026.other.282517

2. Cardiovascular prevention 2022. Russian national guidelines

   S. А. Boytsov, Nana Pogosova, А. А. Аншелес +34

   Maqola20232 iqtibos

   ABIABI:AkademIndex/2026.other.282555